Published: Nov. 12, 2025 (updated intraday, UTC)
Key points at a glance
- Special shareholder meeting (8:00 a.m. ET today): Investors vote on a one‑time option exchange for non‑executive employees; if fully taken up, Moderna estimates a net reduction of ~3.44M options outstanding. [1]
- New 13F-based moves posted today:BNY Mellon cut its MRNA stake by ~16% (to ~1.61M shares) in Q2; Campbell & CO initiated a new ~53k‑share position. [2]
- Stock now: MRNA is trading higher intraday as the market eyes the vote and recent earnings context.
What’s happening today (Nov. 12, 2025)
1) Shareholders vote on employee option exchange
Moderna is holding a virtual special meeting at 8:00 a.m. Eastern to seek approval for a one‑time exchange of “underwater” employee stock options (Executive Committee excluded). Per the definitive proxy, at 100% participation the plan would cancel options for ~5.65M shares and regrant options for ~2.21M, reducing option overhang by ~3.44M shares. The webcast URL and meeting logistics are outlined in the SEC filing. [3]
Why it matters: Lower option overhang can reduce prospective dilution and may aid retention during a turnaround period.
2) Fresh institutional-ownership headlines posted this morning
Two 13F‑driven updates surfaced today:
- Bank of New York Mellon Corp reported a ~16% reduction in its MRNA position to ~1.61M shares as of Q2. [4]
- Campbell & CO Investment Adviser LLCinitiated an MRNA stake (~53,333 shares, ≈$1.47M in Q2 value). [5]
Reminder: 13F disclosures are backward‑looking (quarter‑end holdings), but the news postings are today, adding color to current sentiment and ownership trends.
Market context investors are trading on
Earnings and guidance (last week)
On Nov. 6, Moderna posted Q3 revenue of ~$1.02B (‑45% YoY) and a GAAP loss of $0.51/share, beating consensus on both lines. Management narrowed 2025 revenue guidance to $1.6–$2.0B and detailed cost‑cutting efforts. Shares initially bounced on the better‑than‑feared loss but remain well below 2024 levels. [6]
Pipeline & portfolio snapshots
- CMV program halted: In October, Moderna discontinued the late‑stage CMV vaccine after missing its primary endpoint. [7]
- Flu vaccine (mRNA‑1010) efficacy: A Phase 3 readout showed ~26.6% relative efficacy vs. a licensed standard‑dose flu vaccine in adults 50+ (and ~27.4% in 65+), with broader regulatory submissions targeted into early 2026 per company updates. [8]
- Next‑gen COVID (mNEXSPIKE): The FDA approved Moderna’s lower‑dose, refrigerator‑stable shot earlier this year for 65+ and high‑risk younger groups; subsequent immunogenicity data indicated strong responses against circulating variants. [9]
What to watch after the meeting
- Voting outcome and mechanics: Preliminary results are typically announced at the meeting; final tallies are filed to the SEC on Form 8‑K within four business days, per the proxy. [10]
- Dilution math vs. retention benefit: If the option exchange is approved and launched, monitor how much of the ~5.65M eligible options are actually exchanged—this determines the realized reduction in overhang (theoretical ~3.44M shares at 100% participation). [11]
- Regulatory cadence: Moderna has guided to completing regulatory filings for mRNA‑1010 (seasonal flu) in major markets by January 2026, an important revenue bridge as COVID seasonality and RSV (mRESVIA) normalize. [12]
The bottom line
Today’s Moderna story is dominated by the special shareholder vote—a governance step aimed at retaining talent and trimming option overhang amid a multi‑year reset from pandemic windfalls to a diversified mRNA portfolio. Intraday, MRNA is trading higher as investors weigh the vote, the recent earnings beat, cost controls, and the next slate of regulatory catalysts. (See live price above.)
Sources & further reading
- Special meeting & option exchange (SEC definitive proxy): logistics, vote mechanics, and overhang math. [13]
- Institutional filings posted today: BNY Mellon trims stake; Campbell & CO opens new stake. [14]
- Earnings & guidance (Nov. 6): Q3 recap and narrowed 2025 revenue outlook. [15]
- Flu vaccine efficacy & filing plans: Phase 3 rVE and submission timing. [16]
- Next‑gen COVID vaccine approval & immunogenicity: labels and variant‑era data. [17]
Editorial note: This report compiles items published on Nov. 12, 2025 alongside essential context from the last several weeks so readers have the full picture behind today’s moves. It is not investment advice.
References
1. www.sec.gov, 2. www.marketbeat.com, 3. www.sec.gov, 4. www.marketbeat.com, 5. www.marketbeat.com, 6. www.wsj.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.reuters.com, 10. www.sec.gov, 11. www.sec.gov, 12. www.sec.gov, 13. www.sec.gov, 14. www.marketbeat.com, 15. www.reuters.com, 16. www.reuters.com, 17. www.reuters.com
